Utah Medical Products, Inc. (UTMD) Market Cap & Valuation Ratios
Utah Medical Products, Inc. (UTMD) has a market cap of $236.3M, a trailing P/E of 22.6 and a price-to-sales ratio of 6.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
UTMDUtah Medical Products, Inc.Follow UTMD — free
—
Price chart with a free account
- Market cap
- 236.3M
- P/E TTM
- 22.6
- Dividend yield
- 1.7%
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Peers
medical instruments & supplies · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| UTMD | 0.2 | 22.6 | 4.1 | 12.6 | 4.8% | -7% | 28% | 24% |
| ANGO | 0.5 | — | 1.5 | — | 0.3% | +8% | -11% | -27% |
| DCTH | 0.5 | — | 4.2 | — | 3.5% | +36% | -2% | -3% |
| SGHT | 0.5 | — | 5.4 | — | -4.7% | +9% | -33% | -736% |
| SSII | 0.5 | — | 8.3 | — | -4.0% | +106% | -16% | -24% |
| SI | 0.4 | — | 5.4 | — | -11.5% | +61% | -59% | -31% |
| CARL | 0.4 | — | 5.4 | — | -9.0% | +65% | -61% | -72% |
| EMBC | 0.4 | 4.6 | 1.6 | 6.1 | — | -8% | 22% | 26% |
| OBIO | 0.3 | — | 8.2 | — | — | +986% | -181% | -172% |
| SMTI | 0.3 | — | 3.0 | 29.4 | 1.5% | +13% | 8% | 17% |
| OSUR | 0.3 | — | 1.1 | — | — | -19% | -48% | -36% |
| Median of these 10 | 4.6 | 4.8 | 17.7 | -4.0% | +24% | -25% | -29% |
P/E 22.6 vs. a peer median of 4.6; EV/Sales 4.1 vs. 4.8. UTMD's own P/E sits at the 89th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesUtah Medical Products, Inc. — questions
- What is Utah Medical Products, Inc.'s market cap?
- $236.3M.
- What is Utah Medical Products, Inc.'s P/E ratio?
- 22.6 on trailing twelve-month earnings to 2026-06-30.
- What is Utah Medical Products, Inc.'s price-to-sales ratio?
- 6.5.
Every figure on this page comes from Utah Medical Products, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.